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Abstract Incorporation of ET-18-OCH3 into well-character-
ized liposomes known as ELL-12 has eliminated its gastro-
intestinal and hemolytic toxicity without loss of growth inhibiting
activity. ET-18-OCH3, but not ELL-12, blunted the increase in
membrane protein kinase C (PKC) activity induced by 12-O-
tetradecanoylphorbol 13-myristate (TPA) and markedly reduced
levels of PKCK in NIH 3T3 fibroblasts. Furthermore, prolonged
treatment with ELL-12 neither inhibited TPA-induced translo-
cations of PKCK and PKCN to the particulate fraction nor
caused down-regulation, and did not affect the cellular distribu-
tion of TPA-insensitive PKCj. In Jurkat T cells, where ELL-12
markedly induced apoptosis that was blocked by an inhibitor of
caspase-3-like activities, it had no effect on PKC activity or
translocation induced by TPA. Thus, it seems unlikely that PKC
is involved in the therapeutic effects of ELL-12.
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The ether lipid ET-18-OCH3 has shown a selective inhib-
itory e¡ect on the growth of cultured cancer cells in vitro [1],
in animal models in vivo [2], and has been used in clinical
trials [3]. However, therapeutic utilization of ET-18-OCH3 has
been limited by non-speci¢c membrane detergent e¡ects [4],
which cause gastrointestinal and other toxicities, including
hemolysis [2]. Incorporation of ET-18-OCH3 into liposomes,
composed of dioleoylphosphatidylcholine:cholesterol :glutaric
acid derivatized dipalmitoylphosphatidylethanolamine:ET-18-
OCH3 (4:3:1:2, v/v), known as ELL-12 [5], has eliminated
these side e¡ects, reduced toxicity, expanded the dose range,
and allowed more targeted delivery into tumor cells [6].
Despite extensive investigation, the mechanism of action of
ET-18-OCH3 is not yet fully elucidated. A growing body of
evidence suggests that the antineoplastic e¡ect of this ether
lipid may be due to inhibition of several vital signal trans-
duction pathways [7^9], particularly protein kinase C (PKC),
a ubiquitous protein kinase that transduces growth signals
(for recent reviews see [10,11]). ET-18-OCH3 inhibits the
phosphotransferase activity of PKC in vitro [1,12], acting as
a competitor of phosphatidylserine (PS), a known cofactor of
PKC [12^15]. ET-18-OCH3 also e¡ectively inhibits PKC-de-
pendent phosphorylation of endogenous proteins in human
breast cancer MCF-7 cells, whose growth is markedly inhib-
ited by ET-18-OCH3 [16], and inhibits 12-O-tetradecanoyl-
phorbol 13-myristate (TPA)-induced protein phosphorylation
in intact HL60 cells [17]. Moreover, in HL60 cells, 1-L-D-ara-
binofuranosylcytosine (ara-C)-induced apoptosis was stimu-
lated by pretreatment with ET-18-OCH3, which inhibits
both ara-C- and TPA-induced translocation of PKCLII [18].
ET-18-OCH3 also inhibits TPA-stimulated phospholipase D
activity and DNA synthesis in NIH 3T3 ¢broblasts [19], fur-
ther supporting the notion that PKC is one of the primary
targets of ET-18-OCH3 [19]. Recently, however, it has been
noted that the mode of addition of ET-18-OCH3 to PKC
assays in£uences its e¡ects: when added from an ethanol sol-
ution, ET-18-OCH3 inhibits PKC activity [12^14], whereas
ET-18-OCH3 stimulates PKC activity when added together
with PS and 1,2-diacylglycerol (DAG) as liposomes [20].
Moreover, other studies have shown only a moderate e¡ect
on PKC activity in vitro, and, furthermore, similar inhibitory
e¡ects were found with active and inactive anomers of an
ether lipid [21]. In view of the importance of PKC in signal
transduction and cellular proliferation, we examined whether
ET-18-OCH3, when stably associated with liposomes as ELL-
12, a¡ects PKC in a similar manner as the free form.
2. Materials and methods
2.1. Materials
Anti-PKC-K, -N, and -j antibodies were purchased from Upstate
Biotechnology (Lake Placid, NY), Gibco-BRL (Gaithersburg, MD),
and Transduction Laboratories (Lexington, KY), respectively. TPA
was from Calbiochem (La Jolla, CA). ET-18-OCH3 was from Alexis
Corp. (San Diego, CA) and used from a concentrated ethanol stock
solution. All lipids and other reagents were of the highest purity
available. Ac-DEVD-CHO was from Bachem (King of Prussia, PA).
2.2. Liposome preparation and characterization
ET-18-OCH3 liposome formulation ELL-12 (DOPC/Chol/DOPE-
GA/ET-18-OCH3 (4:3:1:2)), was prepared as previously described
[22] and kept at 4‡C. In all experiments, ELL-12 concentration refers
to the concentration of the of ET-18-OCH3 component in the lipo-
somes.
2.3. Cell culture
NIH 3T3 ¢broblasts and Jurkat T cells were cultured in high glu-
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cose (4.5 g/l) Dulbecco’s modi¢ed Eagle’s medium (DMEM) and
RPMI 1640, respectively, supplemented with 10% FBS, antibiotics
and 2 mM L-glutamine [23].
2.4. Cell fractionation
After washing with cold PBS, NIH 3T3 cells were resuspended in
lysis bu¡er (20 mM Tris-HCl, pH 7.5, 2 mM EDTA, 2 mM EGTA,
25 Wg/ml leupeptin, and 25 Wg/ml aprotinin). All subsequent steps
were carried out at 4‡C as described earlier [24]. Brie£y, the cells
were homogenized by passing 10 times through a 25 gauge needle
with a syringe and centrifuged at 1000Ug for 5 min. Supernatant
was centrifuged at 100 000Ug for 1 h to produce a nuclei-free partic-
ulate membrane fraction (pellet) and a cytosol fraction (supernatant).
Protein concentration was determined by the BCA method (Pierce,
Rockford, IL).
2.5. Measurement of PKC activity
Particulate fractions were solubilized in 100 Wl lysis bu¡er contain-
ing 0.1% (v/v) Triton X-100 by passage through a 27 gauge needle 10
times. After centrifugation for 20 min at 14 000Ug, supernatants were
collected and designated membrane fractions. Equal amounts of pro-
tein (5^10 Wg) from cytosolic and membrane fractions were assayed
for PKC activity using a PKC assay kit (Upstate Biotechnology, Lake
Placid, NY) as described previously [25]. In some cases, cytosolic and
membrane preparations were partially puri¢ed on DEAE cellulose
columns as previously described before assaying PKC activity [24].
2.6. Western analysis
PKC isozymes were analyzed by Western blotting as previously
described [26]. To prevent proteolysis during sample preparation,
cell extracts were prepared in a denaturing, hot SDS bu¡er and
then separated by electrophoresis through a 12% polyacrylamide gel
under reducing conditions. Proteins were transferred to nitrocellulose
membranes and blocked with 3% non-fat milk in PBS containing 0.5%
Tween-20 (TPBS) for 30 min. The membranes were then incubated for
2 h at room temperature with anti-PKC-K, -N, or -j antibodies diluted
at least 500-fold in milk-TPBS, and subsequently with anti-rabbit or
anti-mouse IgG conjugated to horseradish peroxidase (Bio-Rad, Her-
cules, CA). After washing, immunoreactive bands were visualized by
the SuperSignal system (Pierce, Rockford, IL). To compare relative
levels of PKC isozymes, the same blots were stripped several times by
incubating in 50 mM Tris-HCl, pH 6.8, 2% SDS, 0.1% L-mercapto-
ethanol for 1 h at 60‡C and re-probed with another antibody.
2.7. Cell viability assay
Cell viability was measured with a 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT) proliferation/viability kit essen-
tially as described in the manufacturer’s protocol (Boehringer Mann-
heim, Indianapolis, IN). The MTT dye reduction assay measures
mitochondrial respiratory function and can detect the onset of cell
death earlier than dye exclusion based methods. NIH 3T3 ¢broblasts
were seeded in 96 well £at bottom plates and grown to con£uence.
Solutions of ET-18-OCH3 and ELL-12 in culture medium were added
and after 24 h, MTT was added and incubations continued for an
additional 4 h. After removing the medium and washing the cells,
reduced dye was solubilized with 20% SDS in 50% dimethylforma-
mide (pH 4.7) and cell viability assessed from absorbance measure-
ments at 570 and 630 nm.
2.8. [3H]Thymidine incorporation
NIH 3T3 cells were seeded in 24-well plates at 3U104 cells per well,
cultured for 48 h in medium containing 10% serum, and then the
culture medium was replaced with medium containing 2% serum.
Cells were treated with the indicated concentrations of ELL-12 for
18 h and then pulsed with 1 WCi of [3H]thymidine for 6 h. Incorpo-
ration of radioactivity into trichloroacetic acid-insoluble material was
measured as described [27].
2.9. DNA fragmentation assay and staining of apoptotic nuclei
DNA fragmentation measurement and staining of apoptotic nuclei
were carried out as described [28].
3. Results and discussion
3.1. E¡ect of acute ET-18-OCH3 and ELL-12 treatment on
PKC activity
Previously, many investigations have been focused on the
inhibitory actions of antineoplastic ether lipids on PKC [12^
14,16,29,30]. ET-18-OCH3 was proposed to accumulate at the
cell surface with non-saturation kinetics [31] and to compete
with PS at the regulatory domain of PKC isozymes [32]. Thus,
it was suggested that ET-18-OCH3 might decrease the levels
of PKC isozymes by proteolytic down-regulation in a similar
manner as its activators, PS, DAG, and TPA [33]. Due to the
enhanced therapeutic e¡ects of liposome-associated ET-18-
OCH3, it was of interest to compare the e¡ects of ET-18-
OCH3 and ELL-12 on PKC. We have circumvented the short-
comings of previous in vitro approaches by examining the
e¡ects of ELL-12 on NIH 3T3 ¢broblasts, which express
only a limited and well-de¢ned set of PKC isozymes [24],
and have previously been shown to be sensitive to ether lipids
[9,19]. Moreover, ET-18-OCH3 markedly inhibits PKC activ-
ity in these cells [19,34]. Thus, it was of interest to examine
whether ELL-12 alters the e¡ects of TPA on PKC activity
and/or translocation in these cells. As expected, TPA in-
creased membrane-bound PKC activity by 6-8-fold within
15 min (Fig. 1). In agreement with previous studies [19,34],
treatment of NIH 3T3 ¢broblasts with ET-18-OCH3 for 30
min prior to stimulation with TPA prevented the TPA-in-
duced increase in membrane PKC activity (Fig. 1). In con-
trast, pre-incubation with ELL-12 had no e¡ect on PKC ac-
tivity nor did it a¡ect TPA-induced activation of PKC (Fig.
1).
3.2. E¡ect of ET-18-OCH3 and ELL-12 on the level and
membrane translocation of PKC isozymes in NIH 3T3
¢broblasts
In agreement with previous studies [19,34], prolonged treat-
ment of NIH 3T3 ¢broblasts with ET-18-OCH3 resulted in
marked reduction in levels of PKCK (Fig. 2A) and PKCN holo
Fig. 1. E¡ects of acute treatment with ET-18-OCH3 and ELL-12 on
activation of PKC. NIH 3T3 ¢broblasts were incubated with ve-
hicle, ET-18-OCH3 (A, 7.5 WM), or ELL-12 (B, 7.5 WM) for 30 min
and then treated without or with 200 nM TPA for 15 min. ELL-12
concentration refers to the concentration of the of ET-18-OCH3
component in the liposomes. Cells were lysed and PKC in the par-
ticulate fractions was assayed as described in Section 2.5. A and B
are from two independent experiments. Data are means þ S.D. from
a representative experiment carried out in triplicate.
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enzymes (data not shown) in a dose-dependent manner. How-
ever, in contrast to downregulation of PKC with TPA, no
production of proteolytic fragments of PKCK could be de-
tected. In contrast, ELL-12 did not have any signi¢cant e¡ects
on the levels of PKCK and PKCN, even at concentrations as
high as 300 WM. As expected, long term incubation with 1 WM
TPA caused downregulation of cPKCK (Fig. 2B) and PKCN
(data not shown), but not PKCj (Fig. 2C).
Another commonly used assay to demonstrate in vivo acti-
vation of PKC is the intracellular redistribution of this en-
zyme. Upon activation, PKC translocates from the cytosol to
the plasma membrane [35]. To investigate what e¡ect, if any,
ELL-12 has on the translocation of selected PKC species
present in NIH 3T3 ¢broblasts, cells were pre-incubated
with ELL-12 and then stimulated with TPA for short periods
(0^15 min), followed by rapid washing and separation of
membrane fractions from the cytosol. The association of
cPKCK, nPKCN and atypical PKCj isoenzymes with mem-
branes was assessed by Western blot analysis. A liposome
preparation without ET-18-OCH3 served as a control to elim-
inate any non-speci¢c e¡ects of the lipid carrier. As expected,
TPA treatment induced rapid translocation of PKCK to the
membrane fraction (Fig. 2D). In contrast, treatment of the
cells with ELL-12 did not a¡ect the intracellular distribution
of cPKCK (Fig. 2D), or nPKCN (data not shown). It is well
known that atypical PKCj neither binds TPA, nor is capable
of translocation from the cytosol to the plasma membrane in
response to DAG and tumor promoter phorbol esters, such as
TPA. Incubation with increasing concentrations of ELL-12
also had no signi¢cant e¡ect on distribution of atypical
PKCj (Fig. 2E). Moreover, prolonged treatment with ELL-
12 had no signi¢cant e¡ects on TPA-induced translocation of
any of the PKC isoforms.
3.3. E¡ect of ELL-12 treatment on growth and apoptosis of
NIH 3T3 ¢broblasts
Several studies indicate that NIH 3T3 ¢broblasts are mod-
erately sensitive to the cytotoxic actions of ET-18-OCH3
[9,19]. In agreement, we found that prolonged incubation in
serum-free medium with 5, 10, 20, and 100 WM ET-18-OCH3
for 20 h, reduced viability by 0, 20, 45 and 100%, respectively.
We also found that in the presence of serum, the inhibitory
e¡ects of ET-18-OCH3 were much weaker and the IC50 was
shifted to about a 3-fold higher concentration. ELL-12 was 2-
fold less cytotoxic than ET-18-OCH3, in concordance with
previous results showing that associating ET-18-OCH3 with
liposomes abrogated non-speci¢c cell membrane-associated
lytic e¡ects [6,36]. However, ELL-12 still has a growth inhib-
itory e¡ect in media containing 2% serum as measured by
[3H]thymidine incorporation (Fig. 3A). A signi¢cant e¡ect
was observed at concentrations as low as 10 WM with a max-
imum inhibition at 50 WM.
A previous study demonstrated that ELL-12, similar to ET-
18-OCH3, can induce the formation of DNA laddering, a
characteristic of apoptosis, in murine leukemia cells [36].
Thus, it was of interest to examine whether ELL-12 causes
apoptosis of NIH 3T3 ¢broblasts. Serum deprivation induced
apoptosis of NIH 3T3 ¢broblasts, where shrinking, blebbing,
and condensation of nuclei were clearly evident after 24 h.
Fig. 2. E¡ects of ET-18-OCH3 and ELL-12 on levels of PKC isoen-
zymes. Con£uent monolayers of NIH 3T3 ¢broblasts were treated
for 20 h with vehicle (Con), with empty liposomes (ET-18-OCH3-
free) at a concentration equivalent to the highest dose of ELL-12
(lp), or with the indicated concentrations of ET18-O-CH3 (ET-18),
ELL-12, or TPA (1 WM) alone. Cells were then lysed and lysates
(30 Wg) were resolved on SDS-PAGE gels and analyzed by Western
blotting with the corresponding anti-PKC isozyme antibodies, anti-
PKCK (A, B) and anti-PKCj (C). Results are from separate experi-
ments with di¡erent exposure times. D, E: E¡ect of long-term ELL-
12 pretreatment on TPA-induced translocation of PKC isozymes
from the cytosol to the particulate fraction. NIH 3T3 ¢broblasts
were incubated for 20 h with the indicated concentrations of ELL-
12, or control liposome preparation without ET-18-OCH3 (lp), fol-
lowed by 15 min stimulation with vehicle (3) or with (+) TPA (200
nM). Cells were harvested and extracted in cell lysis bu¡er and frac-
tionated into cytosol (C) and nuclei-free, particulate (P) fractions,
prepared as described in Section 2.5. Proteins (30 Wg) were resolved
on 8% SDS-PAGE, transferred to nitrocellulose membranes, probed
with speci¢c monoclonal anti-PKC antibodies, and visualized by en-
hanced chemiluminescence detection.
Fig. 3. E¡ects of ELL-12 on proliferation and apoptosis of NIH
3T3 ¢broblasts. A: NIH 3T3 ¢broblasts were incubated in media
containing 2% fetal calf serum for 20 h in the presence of the indi-
cated concentrations of ELL-12 and [3H]thymidine incorporation
was measured. B: NIH 3T3 ¢broblasts were cultured in serum-free
medium in the presence of the indicated concentrations of ELL-12
and percent apoptotic cells was evaluated with the DNA-speci¢c £u-
orochrome bisbenzimide. Data are means þ S.D. from a representa-
tive experiment carried out in triplicate.
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Treatment of NIH 3T3 ¢broblasts with 20 WM ELL-12
slightly enhanced the appearance of apoptotic nuclei induced
by serum starvation and a signi¢cant e¡ect was observed at a
concentration of 200 WM (Fig. 3B). In contrast, the presence
of serum totally prevented apoptosis even in the presence of
200 WM ELL-12. These observations are similar to those of a
previous report demonstrating that untransformed NIH 3T3
¢broblasts cultured in the presence of serum are resistant to
the apoptotic e¡ects of ET-18-OCH3 [37].
3.4. ELL-12 markedly induces apoptosis of Jurkat T cells
without a¡ecting PKC activity
Because human leukemic cell lines are highly sensitive to
ET-18-OCH3 and readily undergo apoptosis after exposure to
this ether lipid, we examined the e¡ect of ELL-12 on apop-
tosis and PKC activity in Jurkat T cells. In agreement with
previous studies [18,37,38], ET-18-OCH3 markedly induced
apoptosis of Jurkat T cells as measured by a quantitative
DNA fragmentation assay at a concentration as low as
2 WM (Fig. 4A). ELL-12 also caused extensive cell death in
these cells in a dose-dependent manner (Fig. 4B). In contrast,
treatment of cells with liposomes devoid of ET-18-OCH3 did
not have any signi¢cant e¡ects (Fig. 4B). Blebbing of cell
membranes was observed in almost all cells and cells were
fragmented into characteristic condensed nuclei and apoptotic
bodies, whereas untreated cells did not show any morpholog-
ical changes (data not shown). It should be pointed out that,
similar to the e¡ects of ET-18-OCH3, ELL-12 induced apop-
tosis very rapidly and apoptosis was clearly evident after only
5 h of treatment (Fig. 4B).
Activation of the executionary caspases, especially caspase-
3, -6, and -7, represent a converging downstream point in the
apoptotic pathway leading to proteolysis of nuclear targets,
such as poly(ADP-ribose) polymerase (PARP) and lamins,
which are involved in the morphological nuclear changes as-
sociated with apoptosis (reviewed in [39]). To examine their
role in ELL-12-induced apoptosis, we utilized an irreversible
inhibitor, Ac-DEVD-CHO, a tetrapeptide aldehyde corre-
sponding to the motif that is cleaved in PARP, which inhibits
a wide spectrum of caspase-3-like caspases [39]. As shown in
Fig. 5A, Ac-DEVD-CHO abolished DNA fragmentation in-
duced by ELL-12 in a dose-dependent manner. Signi¢cant
inhibition was observed at a concentration of Ac-DEVD-
CHO as low as 10 WM and complete reversal was observed
at 50 WM (Fig. 5A). Similarly, Ac-DEVD-CHO abolished the
morphological features associated with apoptosis, including
condensation of nuclei and formation of apoptotic bodies
(data not shown). Although ET-18-OCH3 markedly inhibits
PKC in human leukemic cell lines [17,18], treatment with 10
and 50 WM ELL-12 had no signi¢cant e¡ects on PKC activity
or on translocation induced by TPA (Fig. 5B). These results
are similar to those obtained with NIH 3T3 ¢broblasts (Fig.
1).
In summary, our studies with ELL-12 reinforce previous
¢ndings that inhibition of PKC by ET-18-OCH3 may be im-
portant for its anti-proliferative activities [1,12^19]. However,
the possibility cannot be excluded that a non-speci¢c ‘deter-
gent e¡ect’ of ET-18-OCH3 in£uences PKC activity. The
much less cytotoxic, but very potent antineoplastic ELL-12
form does not alter PKC activity nor induces down-regulation
of PKCK, PKCN, or PKCj, suggesting that targeted delivery
of ET-18-OCH3 into cells eliminated non-speci¢c membrane
perturbations. Moreover, ELL-12 has no e¡ect on TPA-in-
duced redistribution of PKC isoenzymes. Even in the highly
sensitive human leukemic Jurkat T cell line, where ELL-12
markedly induced apoptosis, it had no e¡ect on PKC activity
or translocation induced by TPA. Our results indicate that the
potent antitumor e¡ect of the liposome formulation of ET-18-
OCH3, ELL-12, must result from actions on other intracellu-
lar targets in vivo.
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